Deals in Depth: September 2009
Boston Scientific's lawsuit settlement with Cordis and concurrent IP license topped the alliance list at $716 million. Even without counting the two monster IPOs by Talecris ($550 million) and China's Sinopharm ($1.1 billion), total money raised in biopharma still increased in September by 26%. Device financing decreased by over $100 million to $266 million.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.